Exhaled breath condensate (EBC) biomarkers in pulmonary fibrosis
- 10 January 2012
- journal article
- Published by IOP Publishing in Journal of Breath Research
- Vol. 6 (1), 16004
- https://doi.org/10.1088/1752-7155/6/1/016004
Abstract
The diffuse parenchymal lung diseases (DPLDs) are a group of clinicopathological entities which have recently undergone reclassification. The commonest type of idiopathic DPLD is interstitial pulmonary fibrosis (PF), which is histologically characterized by usual interstitial pneumonia (UIP), with inflammatory changes in the alveoli and subsequent collagen deposition. A similar type of inflammatory change can also be seen with connective tissue disorders. Many mediators are involved, but it is difficult to study these in a non-invasive manner in patients. The aim of the study detailed in this paper was to investigate inflammatory and oxidative stress biomarkers in PF and correlate these with lung function. 20 PF patients and 20 controls participated in the study. Exhaled breath condensate (EBC) was collected over 10 min using a refrigerated condenser, after fractional exhaled nitric oxide (FeNO) and carbon monoxide (eCO) measurement. EBC total nitrogen oxides (NOx), hydrogen peroxide (H(2)O(2)), 8-isoprostane (8-iso), 3-nitrotyrosine (3-NT), pH and total protein were measured. EBC biomarkers were significantly raised in PF compared with controls: EBC 3-NT (2.5 (0.7-8.9) versus 0.3 (0.1-1.1) ng ml(-1), p = 0.02); pH (7.6 ± 0.3 versus 7.4 ± 0.2, p = 0.004); 8-isoprostane (0.2 (0.1-0.4) versus 0.08 (0.04-0.2) ng ml(-1), p = 0.04) and total protein (24.7 ± 21.1 versus 10.7 ± 7.0 µg ml(-1), p = 0.008). FeNO and eCO were also increased (8.6 (7.1-10.4) versus 6.6 (5.6-7.8) ppb, p = 0.04, and 4.5 ± 1.7 versus 2.7 ± 0.7 ppm, p = 0.001, respectively), but no significant differences were found for NOx or H(2)O(2). In conclusion, inflammatory and oxidative stress biomarkers are raised in patients with PF compared with controls. EBC may be useful for detecting and monitoring lung inflammation in PF.This publication has 41 references indexed in Scilit:
- Review: Analysis of exhaled breath condensate in respiratory medicine: methodological aspects and potential clinical applicationsTherapeutic Advances in Respiratory Disease, 2007
- Comparison of Biomarkers in Exhaled Breath Condensate and Bronchoalveolar LavageAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Analysis of exhaled breath condensate for monitoring airway inflammationTrends in Pharmacological Sciences, 2002
- Indirect monitoring of lung inflammationNature Reviews Drug Discovery, 2002
- American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial PneumoniasAmerican Journal of Respiratory and Critical Care Medicine, 2002
- Collection and Analysis of Exhaled Breath Condensate in HumansAmerican Journal of Respiratory and Critical Care Medicine, 2001
- Exhaled Markers of Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2001
- Exhaled markers of inflammationCurrent Opinion in Allergy and Clinical Immunology, 2001
- Idiopathic Pulmonary Fibrosis: Diagnosis and TreatmentAmerican Journal of Respiratory and Critical Care Medicine, 2000
- Exhaled and nasal nitric oxide measurements: recommendations. The European Respiratory Society Task ForceEuropean Respiratory Journal, 1997